Veracyte (VCYT) Stock Forecast & Price Target

Veracyte Inc. demonstrated strong financial performance, reporting a non-GAAP operating margin of 28.8%, which reflects an increase of 830 basis points year-over-year, and an adjusted EBITDA margin of 30.1%, rising 650 basis points over the same period. The genomic test volume surged by 18%, highlighting robust demand for its diagnostics, particularly with noteworthy growth in urology and thyroid testing, which contributed to record test numbers. Furthermore, management's upward revision of the adjusted EBITDA margin guidance for 2025 to approximately 25.0% indicates confidence in continued operational efficiency and revenue growth potential.

Veracyte faces significant risks that contribute to a negative outlook on its stock, notably regarding weaker-than-expected sales from its Decipher and Afirma tests, which could adversely affect operating margins and free cash flow. Additionally, the company reported a decline in revenue per test in 3Q25 compared to the prior year, coupled with a reduction in adjusted EBITDA margin guidance for 2026, indicating potential operational challenges. Although genomic test volume showed growth, the decrease in overall growth rate and substantial declines in biopharmaceutical services revenue signal underlying vulnerabilities that could affect future performance.